



It's a Done Deal

\$9,040,000



Follow-On

Sole Placement Agent

FEBRUARY 2024

## ROTH MKM Acted as Sole Placement Agent for Tenax Therapeutics, Inc. (Nasdaq: TENX) in its \$9 Million Follow-On

### For more information please contact:

#### Investment Banking

[James Antonopoulos](#)

Managing Director &  
Head of Healthcare  
Investment Banking  
(646) 358-1906

[jantonopoulos@roth.com](mailto:jantonopoulos@roth.com)

[Aparna Beeram](#)

Senior Vice President  
Investment Banking  
(646) 358-1912

[abeeram@roth.com](mailto:abeeram@roth.com)

#### Equity Capital Markets

[Aaron Gurewitz](#)

President & Head of  
Investment Banking  
(949) 720-5703

[agurewitz@roth.com](mailto:agurewitz@roth.com)

[Nazan Akdeniz](#)

COO &  
Managing Director

### Transaction Information

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced the closing of a public offering of (i) 1,600,000 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 3,200,000 shares of its common stock (the "Common Warrants") at a purchase price of \$5.65 per share and associated Common Warrant. The Common Warrants will have an exercise price of \$5.65 per share, are immediately exercisable, and will expire five years after their initial exercise date. The offering closed on February 12, 2024.

ROTH MKM acted as exclusive placement agent in the offering.

### About Tenax Therapeutics

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company owns North American rights to develop and commercialize IV, subcutaneous, and oral formulations of

Equity Capital Markets  
(949) 720-5740  
[nakdeniz@roth.com](mailto:nakdeniz@roth.com)

Lou Ellis  
Managing Director  
Equity Capital Markets  
(949) 720-5739  
[lellis@roth.com](mailto:lellis@roth.com)

levosimendan. Tenax Therapeutics also is developing a unique oral formulation of imatinib. For more information, visit [www.tenaxthera.com](http://www.tenaxthera.com). Tenax's common stock is listed on The Nasdaq Stock Market LLC under the symbol "TENX".

*(Source: Company Website 2.8.24)*

#### **About ROTH MKM**

ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on ROTH MKM, please visit [www.roth.com](http://www.roth.com).

---

[About ROTH MKM](#) | [Investment Banking](#) | [Capital Markets](#) | [Institutional Sales & Trading](#)  
[Research](#) | [Corporate Services](#) | [Corporate Access & Conferences](#) | [Press Room](#)

---

Date of Announcement: 2.13.24

The material, information and facts discussed in this announcement other than the information regarding ROTH MKM and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2024.

**Roth Capital Partners, LLC**

888 San Clemente Drive, Newport Beach CA 92660 | Member SIPC/FINRA | [www.roth.com](http://www.roth.com)

